Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Index
-
Market Cap
27.69M
Enterprise Value
64.71M
Income
-9.78M
Sales
85.53M
Book/sh
2.23
Cash/sh
1.57
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
339
IPO
Dec 07, 2000
P/E
-
Forward P/E
13.95
PEG
-
P/S
0.32
P/B
2.76
P/C
3.90
P/FCF
14.50
EV/EBITDA
10.35
EV/Sales
0.76
Quick Ratio
1.06
Current Ratio
1.99
Debt/Eq
4.39
LT Debt/Eq
4.24
Option/Short
No / Yes
EPS (ttm)
-2.20
EPS next Y
0.44
EPS next Q
-0.21
EPS this Y
-250.00%
EPS next Y
162.86%
EPS next 5Y
-
EPS past 3/5Y
-77.14% -44.59%
Sales past 3/5Y
-8.60% -3.25%
EPS Y/Y TTM
83.35%
Sales Y/Y TTM
-6.42%
EPS Q/Q
93.29%
Sales Q/Q
-4.68%
Insider Own
7.21%
Insider Trans
14.43%
Inst Own
42.56%
Inst Trans
-4.76%
ROA
-12.41%
ROE
-78.65%
ROIC
-18.60%
Gross Margin
54.11%
Oper. Margin
0.72%
Profit Margin
-11.44%
SMA20
0.02%
SMA50
0.89%
SMA200
5.64%
Trades
Shs Outstand
4.51M
Shs Float
4.18M
52W High
9.40 -34.68%
52W Low
3.76 63.52%
Volatility
5.52% 5.50%
ATR (14)
0.35
RSI (14)
50.10
Beta
1.50
Rel Volume
0.20
Avg Volume
39.04K
Volume
7,623
Perf Week
-0.16%
Perf Month
1.66%
Perf Quarter
14.34%
Perf Half Y
-8.41%
Perf YTD
-8.19%
Perf Year
33.62%
Perf 3Y
-89.45%
Perf 5Y
-92.48%
Perf 10Y
-78.07%
Prev Close
6.23
Price
6.14
Change
-1.44%
Date Action Analyst Rating Change Price Target Change
Apr-09-25Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Mar-10-23Upgrade The Benchmark Company Speculative Buy → Buy $3 → $4
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy
Dec-09-20Initiated Northland Capital Outperform $6
Nov-10-20Initiated KeyBanc Capital Markets Overweight $6
Jul-08-19Downgrade Janney Buy → Neutral $2
Jan-24-18Reiterated Janney Buy $5 → $8
Jan-23-18Reiterated The Benchmark Company Buy $6 → $10
Nov-17-16Initiated Singular Research Buy $5.50
Jul-28-15Initiated The Benchmark Company Buy $8
May-20-26 07:30AM
May-12-26 03:01PM
01:08PM
07:40AM
07:30AM
07:30AM Loading…
May-07-26 07:30AM
Apr-28-26 07:30AM
Mar-12-26 03:01PM
12:58PM
07:47AM
07:30AM
Mar-06-26 04:01PM
Mar-03-26 07:30AM
Feb-26-26 07:30AM
Feb-10-26 07:30AM
05:35AM Loading…
Feb-03-26 05:35AM
Jan-30-26 06:49AM
Jan-29-26 04:30PM
Dec-17-25 07:30AM
Nov-06-25 02:05PM
07:31AM
07:00AM
Oct-30-25 08:00AM
Sep-16-25 07:00AM
Sep-09-25 07:00AM
Aug-12-25 03:02AM
Aug-11-25 07:20AM
07:00AM
Aug-08-25 09:33AM
Aug-04-25 04:30PM
07:00AM Loading…
Jul-17-25 07:00AM
Jun-02-25 04:57PM
May-14-25 09:14AM
May-13-25 03:03AM
May-12-25 11:28PM
07:13AM
07:00AM
May-09-25 09:52AM
May-05-25 04:45PM
Apr-10-25 04:45PM
Mar-13-25 01:18AM
Mar-12-25 04:00PM
07:21AM
Feb-24-25 04:45PM
11:00AM
Jan-21-25 09:00AM
Jan-13-25 05:52PM
Nov-08-24 02:08AM
Nov-07-24 07:12AM
07:00AM
Nov-06-24 07:50AM
Oct-29-24 05:00PM
Oct-09-24 05:43PM
Oct-03-24 08:00AM
Sep-18-24 07:30AM
Sep-17-24 08:00AM
Sep-05-24 04:05PM
Aug-08-24 08:37AM
08:30AM
Aug-02-24 08:00AM
Jun-06-24 04:05PM
May-23-24 04:05PM
May-16-24 04:05PM
May-08-24 10:14AM
03:03AM
May-07-24 11:56AM
08:41AM
08:15AM
07:13AM
07:00AM
Apr-29-24 08:45AM
Apr-09-24 09:00AM
Mar-12-24 10:30AM
Mar-11-24 08:00AM
Mar-08-24 10:48AM
Mar-07-24 10:51PM
01:56PM
12:53PM
07:32AM
07:00AM
Mar-06-24 08:30AM
Feb-27-24 05:10PM
Nov-20-23 04:40PM
Nov-09-23 04:30PM
02:28PM
Nov-07-23 09:58PM
08:00AM
07:28AM
07:00AM
Nov-06-23 04:30PM
Oct-30-23 09:00AM
Sep-18-23 08:57AM
Aug-15-23 10:20AM
Aug-08-23 09:43PM
09:15AM
08:05AM
07:18AM
Aug-03-23 06:30PM
Jul-27-23 06:36PM
Jun-22-23 07:55AM
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, China, United Kingdom, and Rest of the World. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
PresidentMr. John Duke
CFOMr. Mark T. Frost
Vice President of Global People OperationsMs. Lori Packer
Senior Vice President of CommercialMr. David Panzarella
Corporate ControllerKathryn Flynn
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frost Mark TChief Financial OfficerMar 16 '26Buy5.005,00025,00017,500Apr 01 09:44 AM
DENELSKY STEPHEN JDirectorMar 17 '26Buy4.8710,00048,70021,000Mar 18 02:13 PM
Snider WilliamDirectorMar 16 '26Buy4.9912,52562,50023,525Mar 18 07:31 AM
Snider WilliamDirectorMar 17 '26Buy4.858,47541,10432,000Mar 18 07:31 AM
Duke John DChief Executive OfficerMar 16 '26Buy5.015,00025,050105,000Mar 17 05:56 PM